Seasonal influenza vaccines: evolutions and future trends

References

• Francis T. The development of the 1943 vaccination study of the Commission on Influenza. Am. J. Hyg.42, 1–11 (1945).
   Google Scholar
• Hirst GK, Rikard ER, Whitman L et al. Antibody response of human beings following vaccination with influenza viruses. J. Exp. Med.75, 495–511 (1942).
   PubMedGoogle Scholar
• Davenport FM. Control of influenza. Med. J. Aust. (Suppl.) 33–38 (1973).
   PubMedGoogle Scholar
• Langmuir AD, Henderson DA, Serfling RE. The epidemiological basis for the control of influenza. Am. J. Pub. Health54, 563–571 (1964).
   PubMed Web of Science ®Google Scholar
• Francis T. Vaccination against influenza. Bull. WHO8725–8741 (1953).
   Google Scholar
• Salk JE, Bailey ML, Laurent AM. The use of adjuvants in studies on influenza immunization. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water-in-oil emulsion. Am. J. Hyg.55, 439 (1952).
   PubMed Web of Science ®Google Scholar
• Woodhour AF, McAleer WJ, Friedman A et al. Antibody response in man to Hong Kong influenza following 1967 formula influenza vaccine in adjuvant 65 (33911). Proc. Soc. Exp. Biol. Med.131, 501–506 (1969).
   PubMed Web of Science ®Google Scholar
• Report to the Medical Research Council by its committee on influenza and other respiratory virus vaccines: clinical trials of oil-adjuvant influenza vaccines, 1960–1963. BMJ2, 267–271 (1964).
   PubMedGoogle Scholar
• Jensen KE, Woodhour AF, Bailey AA. Immunization with polyvalent influenza vaccines. JAMA172, 1230–1238 (1960).
   PubMed Web of Science ®Google Scholar
• Masurel N, Marine WM. Recycling of Asian and Hong Kong influenza A virus hemagglutinins in man. Am. J. Epidemiol.97, 44–49 (1973).
   PubMed Web of Science ®Google Scholar
• La Montagne JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccine – 1978. Rev. Infect. Dis.5, 4723–4736 (1983).
   Google Scholar
• O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Exp. Rev. Vaccines6(5), 1–12 (2007).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine – a randomised controlled trial. Lancet370, 580–589 (2007).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis.191, 1210–1215 (2005).
   PubMed Web of Science ®Google Scholar
• Baras B, Stittelaar KJ, Simon JH et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE3, e1401 (2008).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med.166, 1121–1127 (2006).
   PubMed Web of Science ®Google Scholar
• He XS, Holmes TH, Zhang C et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol.80, 11756–11766 (2006).
   PubMed Web of Science ®Google Scholar
• Frace AM, Klimov AI, Rowe T et al. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine17, 2237–2244 (1999).
   PubMed Web of Science ®Google Scholar
• De Filette M, Ramne A, Birkett A et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine24, 544–551 (2006).
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med.5, 1157–1163 (1999).
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Oh HML et al. A clinical trial of the whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med.358, 2573–2584 (2008).
   PubMed Web of Science ®Google Scholar
• Katz J, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis.160, 195 (1989).
   Google Scholar
• Foy HM, Cooney MK, McMahan R. A Hong Kong influenza immunity three years after immunization. JAMA226, 758–761 (1973).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr.136(2), 168–175 (2000).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med.356, 685–696 (2007).
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med.355, 2513–2522 (2006).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350, 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Foster DA, Talsma A, Furumoto-Dawson A et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am. J. Epidemiol.136, 296–307 (1992).
   PubMed Web of Science ®Google Scholar
• Fedson DS, Wajda A, Nicol JP et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA270, 1956–1961 (1993).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch. Intern. Med.158, 1769–1776 (1998).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Nordin JD, Nelson DB. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med.357, 1373–1381 (2007).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor R, Viboud C et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect. Dis.7, 658–666 (2007).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Nelson JC, Benson P et al. Functional status a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int. J. Epidemiol.35, 345–352 (2006).
   PubMed Web of Science ®Google Scholar
• Monto AS, Rotthoff JR, Teich ER et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin. Infect. Dis.39, 459–464 (2004).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354, 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Xiao-Song H, Holmes TH, Zhang C et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol.80, 11756–11766 (2006).
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Victor JC, Teich ER et al. Prevention of symptomatic seasonal influenza in 2005–2006 by inactivated and live attenuated vaccines. J. Infect. Dis.198, 312–317 (2008).
   PubMed Web of Science ®Google Scholar
• Djulbegovic B, Clarke M. Scientific and ethical issues in equivalence trials. JAMA285, 1206–1208 (2001).
   PubMed Web of Science ®Google Scholar
• Walter EB, Neuzil KM, Zhu Y et al. Influenza vaccine immunogenicity in 6 to 23-month old children: are identical antigens necessary for priming? Pediatrics118, E570–E578 (2006).
   PubMed Web of Science ®Google Scholar